Published in Arthritis Rheum on January 01, 2013
Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood (2015) 1.54
Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol (2014) 1.47
Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. PLoS Pathog (2015) 0.93
Biomarkers Can Identify Pulmonary Tuberculosis in HIV-infected Drug Users Months Prior to Clinical Diagnosis. EBioMedicine (2014) 0.93
An atypical CD8 T-cell response to Chlamydia muridarum genital tract infections includes T cells that produce interleukin-13. Immunology (2014) 0.81
Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther (2016) 0.79
Transforming growth factor-β increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis. Arthritis Res Ther (2015) 0.79
Skin-resident effector memory CD8+CD28- T cells exhibit a pro-fibrotic phenotype in patients with systemic sclerosis. J Invest Dermatol (2016) 0.78
Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int (2017) 0.78
IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease. JCI Insight (2016) 0.77
Interleukin-13 is involved in the formation of liver fibrosis in Clonorchis sinensis-infected mice. Parasitol Res (2016) 0.76
IL-21 Promotes Pulmonary Fibrosis through the Induction of Profibrotic CD8+ T Cells. J Immunol (2015) 0.76
Pediatric Kawasaki Disease and Adult Human Immunodeficiency Virus Kawasaki-Like Syndrome Are Likely the Same Malady. Open Forum Infect Dis (2016) 0.76
The role of the acquired immune response in systemic sclerosis. Semin Immunopathol (2015) 0.75
Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis. Am J Physiol Lung Cell Mol Physiol (2016) 0.75
Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation. PLoS One (2015) 0.75
IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production. J Transl Med (2015) 0.75
Aberrant immune response with consequent vascular and connective tissue remodeling - causal to scleroderma and associated syndromes such as Raynaud phenomenon and other fibrosing syndromes? Curr Opin Rheumatol (2016) 0.75
Pathogenesis of systemic sclerosis-current concept and emerging treatments. Immunol Res (2017) 0.75
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol (2004) 6.75
Scleroderma. N Engl J Med (2009) 6.50
Criteria for the classification of early systemic sclerosis. J Rheumatol (2001) 5.39
Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest (2007) 5.19
IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med (2005) 5.13
CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med (2002) 4.02
CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med (2001) 3.51
Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med (1999) 2.81
Interleukin-4 and interleukin-13 signaling connections maps. Science (2003) 2.69
Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature (1997) 2.56
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum (1999) 2.22
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
Cellular infiltrates in scleroderma skin. Arthritis Rheum (1977) 1.96
Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol (1997) 1.95
Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest (1998) 1.84
Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol (1992) 1.81
Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness. Nat Med (2004) 1.71
The pathogenesis of systemic sclerosis. Annu Rev Pathol (2011) 1.54
Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A (2007) 1.39
Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol (2002) 1.36
Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am (2003) 1.35
Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest (1988) 1.35
Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol (2012) 1.32
Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology (1995) 1.25
Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis (2005) 1.13
Kinetic analysis of the interleukin-13 receptor complex. J Biol Chem (2002) 1.12
Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood (2000) 1.11
Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum (2007) 1.08
Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum (2003) 1.08
Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum (2007) 1.05
Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol (2010) 1.04
Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum (2009) 1.03
CD8+ T cells in asthma: friend or foe? Pharmacol Ther (2008) 1.02
Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol (2004) 1.02
Immune surveillance and effector functions of CCR10(+) skin homing T cells. J Immunol (2002) 1.02
GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum (2011) 1.01
Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway. Lab Invest (2008) 1.00
Tc2 response at the onset of COPD exacerbations. Chest (2008) 0.95
Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem (2004) 0.92
Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol (1997) 0.92
T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol (2008) 0.90
The genetics of systemic sclerosis. Curr Rheumatol Rep (2002) 0.88
Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol (2009) 0.86
IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol (2006) 0.86
Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology (Oxford) (2005) 0.83
Localized scleroderma and systemic sclerosis: is there a connection? Best Pract Res Clin Rheumatol (2007) 0.82
CD8+ T cells in systemic sclerosis. Immunol Res (2011) 0.78
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood (2011) 5.82
Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis (2007) 4.88
Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood (2004) 3.68
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS One (2008) 2.67
WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol (2009) 2.36
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood (2002) 2.02
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum (2003) 1.94
Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension. Am J Respir Crit Care Med (2010) 1.93
Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med (2005) 1.93
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol (2006) 1.85
Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J Immunol (2008) 1.77
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol (2005) 1.66
Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol (2006) 1.64
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.53
CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J Immunol (2005) 1.52
Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood (2013) 1.48
Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) (2012) 1.41
Mitochondrial reactive oxygen species regulate transforming growth factor-β signaling. J Biol Chem (2012) 1.39
Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum (2003) 1.37
The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol (2009) 1.35
Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol (2008) 1.30
PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One (2010) 1.29
Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) (2009) 1.23
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum (2007) 1.23
Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum (2005) 1.18
Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis (2010) 1.18
Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol (2005) 1.18
Differential capability of human cutaneous dendritic cell subsets to initiate Th17 responses. J Immunol (2009) 1.16
Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum (2009) 1.16
Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum (2003) 1.15
Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation. Blood (2010) 1.14
A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum (2003) 1.14
Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol (2012) 1.11
Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol (2007) 1.10
Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol (2011) 1.10
Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis. Am J Respir Crit Care Med (2012) 1.09
Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol (2004) 1.07
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken) (2012) 1.06
Suppression of autoimmune diabetes by soluble galectin-1. J Immunol (2009) 1.06
Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum (2007) 1.05
Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res (2005) 1.04
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) (2014) 1.03
Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum (2006) 1.03
Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum (2009) 1.03
Donor dendritic cell-derived exosomes promote allograft-targeting immune response. J Clin Invest (2016) 1.03
Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum (2009) 1.03
A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum (2012) 1.02
Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells. Apoptosis (2010) 1.01
Methods of analysis of dendritic cell-derived exosome-shuttle microRNA and its horizontal propagation between dendritic cells. Methods Mol Biol (2013) 1.00
Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum (2009) 0.99
Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. Open Rheumatol J (2008) 0.98
Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol (2008) 0.97
In situ-targeting of dendritic cells with donor-derived apoptotic cells restrains indirect allorecognition and ameliorates allograft vasculopathy. PLoS One (2009) 0.97
A peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med (2012) 0.96
Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. Arthritis Rheum (2012) 0.96
Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. J Rheumatol (2008) 0.95
Professional antigen-presenting cells of the skin. Immunol Res (2006) 0.95
Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling. J Immunol (2012) 0.94
Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol (2014) 0.94
Outcome measurements in scleroderma: results from a delphi exercise. J Rheumatol (2007) 0.94
Transgenic galectin-1 induces maturation of dendritic cells that elicit contrasting responses in naive and activated T cells. J Immunol (2006) 0.92
Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res (2007) 0.92
In vivo signaling through the neurokinin 1 receptor favors transgene expression by Langerhans cells and promotes the generation of Th1- and Tc1-biased immune responses. J Immunol (2007) 0.91
Disrupted homeostasis of Langerhans cells and interdigitating dendritic cells in monkeys with AIDS. Blood (2002) 0.90
Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum (2005) 0.90
Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. Blood (2008) 0.90
Scleroderma renal crisis: a pathology perspective. Int J Rheumatol (2010) 0.87
Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respir Res (2014) 0.86
Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken) (2014) 0.86
DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine (2004) 0.85
Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin Rheumatol (2004) 0.85
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum (2004) 0.85
Vitamin D modulates prostaglandin E2 synthesis and degradation in human lung fibroblasts. Am J Respir Cell Mol Biol (2014) 0.84
Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol (2012) 0.83
Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol (2012) 0.83
Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis. Clin Exp Rheumatol (2010) 0.82
Muscle cramps associated with localized scleroderma skin lesions: focal dystonia, neuromyotonia, or nerve entrapment? J Rheumatol (2006) 0.81
Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension. Am J Pathol (2013) 0.81
Quality indicator set for systemic sclerosis. Clin Exp Rheumatol (2011) 0.81
Connective tissue diseases: Predicting death in SSc: planning and cooperation are needed. Nat Rev Rheumatol (2011) 0.80
Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum (2013) 0.80
Overexpression of c-Met and CD44v6 receptors contributes to autocrine TGF-β1 signaling in interstitial lung disease. J Biol Chem (2013) 0.80
Myasthenia gravis and scleroderma: two cases and a review of the literature. Clin Neurol Neurosurg (2007) 0.80
Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis. PLoS One (2012) 0.80
Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J Invest Dermatol (2012) 0.80
Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis. Arthritis Res Ther (2013) 0.79
T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun (2006) 0.78
Daily topical tacrolimus therapy prevents skin rejection in a rodent hind limb allograft model. Plast Reconstr Surg (2009) 0.78
A novel protein highly expressed in testis is overexpressed in systemic sclerosis fibroblasts and targeted by autoantibodies. J Immunol (2003) 0.77
Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2. Am J Respir Cell Mol Biol (2013) 0.77
Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res (Hoboken) (2013) 0.77
Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol (2004) 0.77
Transcriptome analysis reveals differential splicing events in IPF lung tissue. PLoS One (2014) 0.77
Methods of purification of CTL-derived exosomes. Methods Mol Biol (2014) 0.77